Current findings, application, and diagnosis of magnetic resonance imaging in amyotrophic lateral sclerosis
Authors:
Open Access
- 4 November 2026
- journal article
- Published by Walter de Gruyter GmbH in Reviews in the Neurosciences
Abstract
Amyotrophic lateral sclerosis (ALS) is a heterogeneous neurodegenerative disorder within the motor neuron disease (MND) spectrum, characterized by progressive degeneration of upper and lower motor neurons. The clinical phenotype ranges from pure motor syndromes to forms with cognitive and behavioral impairment, and the pathological burden extends beyond the motor system. Diagnosis remains primarily clinical, supported by electrophysiology and exclusion of mimics. Therefore, objective imaging biomarkers are urgently needed. Magnetic resonance imaging (MRI) is widely used as an auxiliary and differential diagnostic tool in ALS. T1- and T2-weighted imaging can assess cortical thickness, gray matter atrophy, and signal changes. Diffusion tensor imaging probes white matter microstructure. Magnetic resonance spectroscopy detects neurochemical alterations. Resting-state functional MRI assesses functional connectivity and network organization. Susceptibility-weighted imaging is sensitive to iron and calcium deposition. Ultra-high-field MRI provides higher resolution and improved metabolite quantification. This critical review summarizes current findings on MRI in ALS, but importantly organizes the evidence by the specific question being addressed: pathological/histological correlates, diagnostic or discriminatory performance, and clinical associations with phenotype, severity, progression, and prognosis. We also discuss major limitations, including methodological heterogeneity, limited standardization, small and clinically heterogeneous cohorts, frequent use of healthy rather than disease controls, and scarce multicenter validation. Although advanced MRI has revealed robust group-level alterations, none of these techniques has yet become established in routine clinical diagnosis of ALS. We, therefore, distinguish promising research findings from validated clinical biomarkers and outline priorities for future translation.Keywords
This publication has 91 references indexed in Scilit:
- Multimodal Neuroimaging‐Guided Stratification in Amyotrophic Lateral Sclerosis Reveals Three Disease Subtypes: A Multi‐Cohort AnalysisHuman Brain Mapping, 2025
- A 65‐year‐old woman with ALS and bilateral precentral motor band signClinical Case Reports, 2024
- Longitudinal Effects of Asymptomatic C9orf72 Carriership on Brain MorphologyAnnals of Neurology, 2022
- MRI Clustering Reveals Three ALS Subtypes With Unique Neurodegeneration PatternsAnnals of Neurology, 2022
- Different sensorimotor mechanism in fast and slow progression amyotrophic lateral sclerosisHuman Brain Mapping, 2021
- Distinct patterns of progressive gray and white matter degeneration in amyotrophic lateral sclerosisHuman Brain Mapping, 2021
- The Distinct Traits of the UNC13A Polymorphism in Amyotrophic Lateral SclerosisAnnals of Neurology, 2020
- Clinical and Molecular Aspects of Senataxin Mutations in Amyotrophic Lateral Sclerosis 4Annals of Neurology, 2020
- Corticospinal tract degeneration in ALS unmasked in T1‐weighted images using texture analysisHuman Brain Mapping, 2018
- Region‐specific impairment of the cervical spinal cord (SC) in amyotrophic lateral sclerosis: A preliminary study using SC templates and quantitative MRI (diffusion tensor imaging/inhomogeneous magnetization transfer)NMR in Biomedicine, 2017